FDA data Registry peer set 1 peer

Alternatives to linaclotide

1 same-class SPL records vs linaclotide - uses, FAERS reaction fields, and OTC/Rx flags from public FDA sources.

Brand: Linzess

Guanylate Cyclase-C Agonist Prescription 1 alternative found

About linaclotide

Linzess is a medicine that helps treat certain bowel problems. It works by helping your bowels move more regularly.

Used for: Linzess is used to treat irritable bowel syndrome with constipation (IBS-C) in adults and children ages 7 and older. It also treats chronic idiopathic constipation (CIC) in adults. Linzess can also treat functional constipation (FC) in children ages 6 and older.

1 Guanylate Cyclase-C Agonist peers (wide set)

Compare linaclotide vs plecanatide side-by-side →

linaclotide vs plecanatide · FAERS reaction fields

FAERS top-reaction field "Diarrhoea" shows the widest count spread between linaclotide and plecanatide in this extract (4,139-report gap on that field). Counts are exposure-weighted submissions, not prevalence rates.

Side Effect linaclotide plecanatide
Diarrhoea 4,502 363
Constipation 1,862 152
Nausea 1,373 159
Fatigue 1,111 106
Abdominal Distension 1,100 100
Abdominal Pain 1,009 96
Headache 982 96
Pain 896 95

"-" means no reports for that reaction. Report counts reflect total FAERS submissions, not prevalence rates.

linaclotide peer mix vs class inventory

Peer mix

0 OTC and 1 Rx SPL records in this peer set (1 total). Class inventory for Guanylate Cyclase-C Agonist: 2 drugs.

Frequently Asked Questions

What same-class SPL records sit beside linaclotide?
This registry lists 1 Guanylate Cyclase-C Agonist medication records beside linaclotide, including plecanatide. Grouping is therapeutic-class indexing from openFDA/SPL, not a product recommendation.

Reading a wide Guanylate Cyclase-C Agonist peer set (1 records)

linaclotide (Linzess) sits in a wide Guanylate Cyclase-C Agonist peer set (1 of 1 class peers shown). Labeled indication field for linaclotide: Linzess is used to treat irritable bowel syndrome with constipation (IBS-C) in adults and children ages 7 and older.

Top FAERS reaction fields for linaclotide total 14,515 reports across 10 reactions, set beside plecanatide. Counts are exposure-weighted submissions, not per-patient risk.

Registry note: Therapeutic-class peer lists are registry indexes, not prescribing advice. This information is for educational purposes only and is not a substitute for professional medical advice. Do not stop or change your medication without talking to your doctor or pharmacist.

Full linaclotide profile →

Field note for linaclotide: see also the generic vs brand label guide when reading Linzess SPL strings.